MedTrace Logo

Study of Entry and Continuation in Care for People Living With HIV in French Guiana

NCT05354934 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-06-09

No results posted yet for this study

Summary

Research Involving the Non-Interventional Human Subject (RIPH category 3). Non-interventional, cross-sectional, multicentre, descriptive and analytical epidemiological study.

A cross-sectional, pseudo-anonymous questionnaire focusing on entry and retention in care will be administered to a sample of PLHIV presenting for consultation in one of the GHT hospitals over a 12-month period.

A sample of 300 PHAs is envisaged to have sufficient power to highlight the main factors associated with periods of loss of sight.

Main objective:

\- To identify factors associated with loss of sight for more than 12 months among people living with HIV in Guyana

Secondary objectives:

* To identify factors associated with a delay in the introduction of ARVs among PLHIV in Guyana
* To describe the perception of the quality of the announcement of the diagnosis of HIV
* To describe the difficulties encountered by PLHIV during their hospital follow-up in French Guyana
* To assess the perceived stigma associated with HIV and its consequences in daily life

Conditions

  • Human Immunodeficiency Virus

Interventions

OTHER

quetionnaire

The questionnaire includes the following modules * Demography and socio-economic conditions * Screening and modalities of discovery and announcement of HIV infection * Time and modalities of introduction of antiretroviral drugs after diagnosis * Knowledge of HIV infection * The perception of follow-up in the health care service * Experiences of stigma * Barriers to accessing care * Periods of loss of sight and reasons for this * Perceived health status, mental health (PHQ4), chronic illness, functional limitations * Addictions * Social network and support * Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization

Sponsors & Collaborators

  • Centre Hospitalier de Cayenne

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-23
Primary Completion
2024-03-23
Completion
2024-06-23

Countries

  • French Guiana

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354934 on ClinicalTrials.gov